These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 23004926)

  • 21. Dilution of botulinum toxin A in lidocaine vs. in normal saline for the treatment of primary axillary hyperhidrosis: a double-blind, randomized, comparative preliminary study.
    Güleç AT
    J Eur Acad Dermatol Venereol; 2012 Mar; 26(3):314-8. PubMed ID: 21492253
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Botulinum toxin type A and B improve quality of life in patients with axillary and palmar hyperhidrosis.
    Rosell K; Hymnelius K; Swartling C
    Acta Derm Venereol; 2013 May; 93(3):335-9. PubMed ID: 23053164
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment of axillary hyperhidrosis with botulinum toxin type A reconstituted in lidocaine or in normal saline: a randomized, side-by-side, double-blind study.
    Vadoud-Seyedi J; Simonart T
    Br J Dermatol; 2007 May; 156(5):986-9. PubMed ID: 17286630
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Botulinum toxin type A in treatment of bilateral primary axillary hyperhidrosis: randomised, parallel group, double blind, placebo controlled trial.
    Naumann M; Lowe NJ
    BMJ; 2001 Sep; 323(7313):596-9. PubMed ID: 11557704
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Hyperhidrosis. Effective reduced sweating with methantheline bromide].
    MMW Fortschr Med; 2012 May; 154(10):68-9. PubMed ID: 22803247
    [No Abstract]   [Full Text] [Related]  

  • 26. Safety and prolonged efficacy of Botulin Toxin A in primary hyperhidrosis.
    D'Epiro S; Macaluso L; Salvi M; Luci C; Mattozzi C; Marzocca F; Salvo V; Scarnò M; Calvieri S; Richetta AG
    Clin Ter; 2014; 165(6):e395-400. PubMed ID: 25524193
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Radiofrequency Thermotherapy for Treating Axillary Hyperhidrosis.
    Schick CH; Grallath T; Schick KS; Hashmonai M
    Dermatol Surg; 2016 May; 42(5):624-30. PubMed ID: 27110892
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Oxybutynin as a treatment for generalized hyperhidrosis: a randomized, placebo-controlled trial.
    Schollhammer M; Brenaut E; Menard-Andivot N; Pillette-Delarue M; Zagnoli A; Chassain-Le Lay M; Sassolas B; Jouan N; Le Ru Y; Abasq-Thomas C; Greco M; Penven K; Roguedas-Contios AM; Dupré-Goetghebeur D; Gouedard C; Misery L; Le Gal G
    Br J Dermatol; 2015 Nov; 173(5):1163-8. PubMed ID: 26114588
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A phase 2a randomized controlled study to evaluate the pharmacokinetic, safety, tolerability and clinical effect of topically applied Umeclidinium in subjects with primary axillary hyperhidrosis.
    Nasir A; Bissonnette R; Maari C; DuBois J; Pene Dumitrescu T; Haddad J; Yamaguchi Y; Dalessandro M
    J Eur Acad Dermatol Venereol; 2018 Jan; 32(1):145-151. PubMed ID: 29055158
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Assessment of quality of life in patients with primary axillary hyperhidrosis before and after suction-curettage.
    Bechara FG; Gambichler T; Bader A; Sand M; Altmeyer P; Hoffmann K
    J Am Acad Dermatol; 2007 Aug; 57(2):207-12. PubMed ID: 17368632
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Correlation between Dermatology Life Quality Index and Minor test and differences in their levels over time in patients with axillary hyperhidrosis treated with botulinum toxin type A.
    Skroza N; Bernardini N; La Torre G; La Viola G; Potenza C
    Acta Dermatovenerol Croat; 2011; 19(1):16-20. PubMed ID: 21489361
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A randomized, blinded clinical evaluation of a novel microwave device for treating axillary hyperhidrosis: the dermatologic reduction in underarm perspiration study.
    Glaser DA; Coleman WP; Fan LK; Kaminer MS; Kilmer SL; Nossa R; Smith SR; O'Shaughnessy KF
    Dermatol Surg; 2012 Feb; 38(2):185-91. PubMed ID: 22289389
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Randomized, Placebo- and Active-Controlled Crossover Study of the Safety and Efficacy of THVD-102, a Fixed-dose Combination of Oxybutynin and Pilocarpine, in Subjects With Primary Focal Hyperhidrosis.
    Pariser DM; Krishnaraja J; Tremblay TM; Rubison RM; Love TW; McGraw BF
    J Drugs Dermatol; 2017 Feb; 16(2):127-132. PubMed ID: 28300854
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Topical glycopyrronium tosylate for the treatment of primary axillary hyperhidrosis: Results from the ATMOS-1 and ATMOS-2 phase 3 randomized controlled trials.
    Glaser DA; Hebert AA; Nast A; Werschler WP; Green L; Mamelok R; Drew J; Quiring J; Pariser DM
    J Am Acad Dermatol; 2019 Jan; 80(1):128-138.e2. PubMed ID: 30003988
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Use of oral oxybutynin at 7.5 mg per day in primary hyperhidrosis].
    Try C; Messikh R; Elkhyat A; Aubin F; Humbert RP
    Rev Med Liege; 2012 Oct; 67(10):520-6. PubMed ID: 23167161
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of microwave thermolysis energy levels on patient-reported outcomes for axillary hyperhidrosis and osmidrosis.
    Grove GL; Togsverd-Bo K; Schwensen JFB; Andersson NW; Nissen CV; Zachariae C; Haedersdal M
    Lasers Surg Med; 2023 Jan; 55(1):105-115. PubMed ID: 36229952
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of botulinum toxin type A on quality of life measures in patients with excessive axillary sweating: a randomized controlled trial.
    Naumann MK; Hamm H; Lowe NJ;
    Br J Dermatol; 2002 Dec; 147(6):1218-26. PubMed ID: 12452874
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Topical Oxybutynin 10% Gel for the Treatment of Primary Focal Hyperhidrosis: A Randomized Double-blind Placebo-controlled Split Area Study.
    Artzi O; Loizides C; Zur E; Sprecher E
    Acta Derm Venereol; 2017 Oct; 97(9):1120-1124. PubMed ID: 28654131
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tumescent suction curettage versus minimal skin resection with subcutaneous curettage of sweat glands in axillary hyperhidrosis.
    Wollina U; Köstler E; Schönlebe J; Haroske G
    Dermatol Surg; 2008 May; 34(5):709-16. PubMed ID: 18318727
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A novel lotion formulation of 20% oxybutynin hydrochloride for the treatment of primary palmar hyperhidrosis: A randomized, placebo-controlled, double-blind, phase III study.
    Fujimoto T; Terahara T; Okawa K; Inakura H; Hirayama Y; Yokozeki H
    J Am Acad Dermatol; 2023 Jul; 89(1):62-69. PubMed ID: 36990320
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.